Therefore, it could be also plausible that IL-4 and/or IL-13 inhibitors as well as IL-31 inhibitors could be not only safe but also beneficial for patients with CTCL [36] (Figure 1). This evidence concerns the gene IL4 and primary cutaneous T-cell non-Hodgkin lymphoma.